Cancer drug development may have overlooked a critical cellular enzyme that enables aggressive tumors to thrive. While researchers have long focused on blocking RAS proteins directly, this finding suggests targeting their processing machinery could offer a more effective therapeutic approach for certain treatment-resistant cancers.
The study demonstrates that isoprenylcysteine carboxyl methyltransferase (ICMT) plays an essential role in BRAFV600E-driven tumor progression by facilitating membrane localization of INPP5E, a phosphatase protein. BRAFV600E mutations occur in approximately 50% of melanomas and significant percentages of other cancers, making them high-priority therapeutic targets. The research reveals that ICMT-mediated methylation allows INPP5E to properly associate with cellular membranes, where it supports oncogenic signaling pathways that drive tumor growth.
This mechanism represents a potentially significant shift in cancer therapy strategy. Current BRAF inhibitors often face resistance as tumors develop workaround pathways, but targeting ICMT could disrupt multiple downstream effects simultaneously. The enzyme processes numerous CAAX-motif proteins beyond RAS, suggesting inhibition might create broader anticancer effects than previously recognized. However, the therapeutic window remains unclear since ICMT likely processes essential proteins in healthy cells as well. Early-stage research will need to determine whether selective ICMT inhibition can preferentially impact tumor cells without causing prohibitive toxicity. If successful, this approach could provide new treatment options for patients with BRAF-mutant cancers who have exhausted current therapeutic alternatives, particularly in melanoma and colorectal cancer where these mutations are prevalent.